Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Novavax (NVAX) Announces 'Going Concern' Qualification
February 28, 2023 4:06 PM ESTNovavax (NASDAQ: NVAX) announced:
Financial Framework
In 2023, Novavax intends to focus the organization to align our investments and activities with our top priority of delivering an updated Covid-19 vaccine consistent with public health recommendations for strain composition for the 2023 fall vaccination season. To... More
Novavax (NVAX) Misses Q4 EPS by $1.09
February 28, 2023 4:03 PM ESTNovavax (NASDAQ: NVAX) reported Q4 EPS of ($2.28), $1.09 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $357 million versus the consensus estimate of $383.14 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
... More